Literature DB >> 11601129

Morphometry confirms the presence of considerable nuclear size overlap between "small cells" and "large cells" in high-grade pulmonary neuroendocrine neoplasms.

A M Marchevsky1, A A Gal, S Shah, M N Koss.   

Abstract

We morphometrically evaluated 5-micron H&E-stained sections from 28 surgically resected high-grade pulmonary neuroendocrine neoplasms, including 16 small cell lung carcinomas (SCLCs) and 12 large cell neuroendocrine carcinomas (LCNECs). For each case, 200 tumor nuclei and 20 to 100 normal lymphocytes were measured. The frequency distributions of tumor cell/lymphocyte (TC/L) size ratios were plotted in bins ranging from 1 to 6, classified into 6 histogram types with TC/L size ratio peaks ranging from 2 to 6 (A-E) and a histogram with a wide distribution (F). SCLCs fit histograms A through E; LCNECs, A through F. Morphometry demonstrated considerable nuclear size overlap in high-grade neoplasms. Approximately one third of SCLCs exhibited considerable numbers of neoplastic cells that were larger than 3 normal lymphocytes, while 4 of 12 LCNECs had a predominant number of small cells. Ten tumors exhibited a B histogram with a "borderline" peak TC/L of 3. The rule that a TC/L size ratio larger than 3 helps distinguish "large" from "small" neoplastic cells was confirmed in only 9 of 28 cases. The use of more generic terminology such as "high-grade neuroendocrine carcinoma" or "grade III neuroendocrine carcinoma" for SCLC and LCNEC is discussed.

Entities:  

Mesh:

Year:  2001        PMID: 11601129     DOI: 10.1309/H40B-8W14-4Q47-03EP

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  20 in total

1.  A subset of high-grade pulmonary neuroendocrine carcinomas shows up-regulation of matrix metalloproteinase-7 associated with nuclear beta-catenin immunoreactivity, independent of EGFR and HER-2 gene amplification or expression.

Authors:  Giuseppe Pelosi; Aldo Scarpa; Giulia Veronesi; Lorenzo Spaggiari; Barbara Del Curto; Patrick S Moore; Patrick Maisonneuve; Angelica Sonzogni; Michele Masullo; Giuseppe Viale
Journal:  Virchows Arch       Date:  2005-09-13       Impact factor: 4.064

2.  Clinical relevance of neuroendocrine differentiation in non-small cell lung cancer assessed by immunohistochemistry: a retrospective study on 405 surgically resected cases.

Authors:  William Sterlacci; Michael Fiegl; Wolfgang Hilbe; Jutta Auberger; Gregor Mikuz; Alexandar Tzankov
Journal:  Virchows Arch       Date:  2009-08-04       Impact factor: 4.064

3.  High Expression of CARM1 Inhibits Lung Cancer Progression by Targeting TP53 by Regulating CTNNB1.

Authors:  Bing Hu; Xin Li; Ling Chen; Zhongliang Liu
Journal:  Lung       Date:  2020-02-07       Impact factor: 2.584

Review 4.  Classification of lung neuroendocrine tumors: lights and shadows.

Authors:  Marco Volante; Gaia Gatti; Mauro Papotti
Journal:  Endocrine       Date:  2015-03-21       Impact factor: 3.633

Review 5.  Unraveling tumor grading and genomic landscape in lung neuroendocrine tumors.

Authors:  Giuseppe Pelosi; Mauro Papotti; Guido Rindi; Aldo Scarpa
Journal:  Endocr Pathol       Date:  2014-06       Impact factor: 3.943

Review 6.  Update on large cell neuroendocrine carcinoma.

Authors:  Kenzo Hiroshima; Mari Mino-Kenudson
Journal:  Transl Lung Cancer Res       Date:  2017-10

Review 7.  Classification of pulmonary neuroendocrine tumors: new insights.

Authors:  Giuseppe Pelosi; Angelica Sonzogni; Sergio Harari; Adriana Albini; Enrica Bresaola; Caterina Marchiò; Federica Massa; Luisella Righi; Gaia Gatti; Nikolaos Papanikolaou; Namrata Vijayvergia; Fiorella Calabrese; Mauro Papotti
Journal:  Transl Lung Cancer Res       Date:  2017-10

8.  Classification of individual lung cancer cell lines based on DNA methylation markers: use of linear discriminant analysis and artificial neural networks.

Authors:  Alberto M Marchevsky; Jeffrey A Tsou; Ite A Laird-Offringa
Journal:  J Mol Diagn       Date:  2004-02       Impact factor: 5.568

Review 9.  Neuroendocrine Tumors of the Urinary Bladder According to the 2016 World Health Organization Classification: Molecular and Clinical Characteristics.

Authors:  Erik Kouba; Liang Cheng
Journal:  Endocr Pathol       Date:  2016-09       Impact factor: 3.943

10.  Interobserver variability in diagnosing high-grade neuroendocrine carcinoma of the lung and comparing it with the morphometric analysis.

Authors:  Seung Yeon Ha; Joungho Han; Wan-Seop Kim; Byung Seong Suh; Mee Sook Roh
Journal:  Korean J Pathol       Date:  2012-02-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.